Supernus' SPN810 meets ADHD endpoints

Supernus Pharmaceuticals Inc. (Rockville, Md.) said oral SPN810 met the secondary efficacy endpoint of significantly reducing conduct problems from baseline as measured by the conduct problem subscale...